artilcle1 - Original Paper Digestion 2010;81:7885 DOI...

Info icon This preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Fax +41 61 306 12 34 E-Mail [email protected] www.karger.com Original Paper Digestion 2010;81:78–85 DOI: 10.1159/000253855 Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease Cristina Nichita a Marc Stelle a Stephan Vavricka b Abdou El-Wafa Ali c Pierluigi Ballabeni d Philippe de Saussure e Alex Straumann f Gerhard Rogler b Pierre Michetti a a Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, b Department of Internal Medicine, Division of Gastroenterology, University Hospital, Zurich, c Pourtalès Hospital, Neuchâtel, d Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, e Division of Hepatogastroenterology, Geneva University Hospital, Geneva, and f Department of Gastroenterology, Kantonsspital, Olten, Switzerland Results: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4–6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smok- ing status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4–6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall. Conclusion: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long- term effectiveness. Copyright © 2010 S. Karger AG, Basel Key Words Crohn’s disease Adalimumab Response, adalimumab Remission, Crohn’s disease Abstract Background: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with mod- erate-to-severe Crohn’s disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. Aim: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice- based patients with moderate-to-severe CD. Methods: We retrospectively reviewed the charts of CD patients who re- ceived adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remis- sion was defined as an HBI of ^ 4 and response as a reduc- tion in the HBI of 1 3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response. Received: April 30, 2009 Accepted: October 5, 2009 Published online: January 12, 2010 Cristina Nichita, MD Department of Gastroenterology and Hepatology Centre Hospitalier Universitaire Vaudois Rue du Bugnon, 46, CH–1011 Lausanne (Switzerland) Tel. +41 21 31 40 706, Fax +41 21 31 40 707, E-Mail cristina.nichita @ chuv.ch © 2010 S. Karger AG, Basel 0012–2823/10/0812–0078$26.00/0 Accessible online at: www.karger.com/dig C.N. and M.S. contributed equally to this work.
Image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}

What students are saying

  • Left Quote Icon

    As a current student on this bumpy collegiate pathway, I stumbled upon Course Hero, where I can find study resources for nearly all my courses, get online help from tutors 24/7, and even share my old projects, papers, and lecture notes with other students.

    Student Picture

    Kiran Temple University Fox School of Business ‘17, Course Hero Intern

  • Left Quote Icon

    I cannot even describe how much Course Hero helped me this summer. It’s truly become something I can always rely on and help me. In the end, I was not only able to survive summer classes, but I was able to thrive thanks to Course Hero.

    Student Picture

    Dana University of Pennsylvania ‘17, Course Hero Intern

  • Left Quote Icon

    The ability to access any university’s resources through Course Hero proved invaluable in my case. I was behind on Tulane coursework and actually used UCLA’s materials to help me move forward and get everything together on time.

    Student Picture

    Jill Tulane University ‘16, Course Hero Intern